Skip to main content
. 2019 Nov 30;24(4):747–757. doi: 10.1007/s10029-019-02091-8

Table 3.

Descriptive statistics of the included AOK cases (2013–2015), presented as a total figure and in accordance with volume categories (I: 1–50, II: 51–75, III: 76–100, IV: 101–125, V: ≥ 126 inguinal hernia repairs per year)

Total I II III IV V
Caseloads, age and gender
 Annual caseload 1–50 51–75 76–100 101–125 ≥ 126
 AOK cases (N) 133.449 4.586 12.105 17.985 20.776 77.997
 Age (median; IQR) 59 (47–73) 60 (49–74) 61 (48–74) 60 (48–74) 60 (48–73) 59 (47–73)
 Gender (female, %) 11.33 11.16 10.04 11.15 11.20 11.61
Risk factors and surgical technique (%)
 Recurrence present on admission 11.66 12.10 11.31 12.12 11.77 11.55
 Incarceration 9.42 10.64 11.93 11.10 9.86 8.45
 Gangrene 0.44 0.48 0.45 0.50 0.46 0.42
 Emergency 4.08 4.62 5.15 4.96 4.36 3.60
 Bilateral procedure 15.61 9.97 11.55 12.64 14.56 17.53
 Intestinal procedure 0.35 0.44 0.35 0.42 0.32 0.34
 Simultaneous repair of umbilical hernia 5.35 3.99 4.38 4.73 4.93 5.84
 Simultaneous repair of femoral hernia 0.38 0.44 0.36 0.36 0.37 0.39
 Simultaneous repair of incisional hernia 0.32 0.26 0.28 0.33 0.32 0.32
 Outpatient repair 11.21 13.06 12.43 11.08 11.79 10.79
 Open suture procedure 6.20 10.60 7.45 7.09 5.37 5.76
 Open mesh procedure 37.92 49.30 43.89 41.03 40.85 34.82
 Minimally invasive mesh procedure 55.89 40.10 48.66 51.88 53.78 59.42
Preoperative medication (%)
 Immunosuppressants 0.74 0.76 0.70 0.71 0.73 0.75
 Systemic glucocorticoids 1.70 1.92 1.76 1.85 1.55 1.69
 Antithrombotics 13.10 14.17 14.46 13.88 13.72 12.48
 Treatment for chronic inflammatory bowel disease 0.32 0.31 0.37 0.36 0.34 0.31
BMI and Elixhauser comorbiditiesa (%)
 Obesity grade, unspecified 0.30 0.44 0.23 0.37 0.26 0.30
 Grade I obesity 2.79 3.47 2.73 2.66 2.81 2.79
 Grade II obesity 0.93 1.02 0.98 0.86 1.04 0.91
 Grade III obesity 0.36 0.57 0.40 0.36 0.34 0.35
 Hypertension, no complications 31.34 34.89 34.69 33.37 32.36 29.87
 Cardiac arrhythmia 8.02 9.16 9.24 9.13 8.39 7.41
 Diabetes, no complications 7.22 8.70 7.73 8.01 7.47 6.81
 Chronic lung disease 5.38 6.13 6.39 5.67 5.35 5.12
 Hypothyroidism 4.32 4.21 4.22 4.24 4.24 4.39
 Congestive heart disease 3.37 4.27 4.22 3.96 3.71 2.95
 Real failure/insufficiency 3.13 3.92 3.88 3.46 3.46 2.80
 Peripheral occlusive vascular disease 2.30 2.94 2.45 2.67 2.37 2.13
 Disorders of the water and electrolyte balance as well as of the acid–base balance 1.97 2.25 2.19 2.16 1.94 1.88
 Other neurologic diseases 1.92 2.35 2.00 2.17 2.04 1.78
 Heart valve disease 1.82 2.18 2.08 2.20 1.85 1.67
 Coagulopathy 1.68 1.92 1.96 1.88 1.75 1.56
 Depression 1.66 2.20 1.86 1.83 1.70 1.54
 Hypertension, with complications 1.55 1.92 1.74 1.79 1.74 1.38

aComorbidities with a total incidence of less than 1% are not presented (diabetes with complications, liver disease, alcohol abuse, paralysis, rheumatoid disease, psychosis, pulmonary heart disease and diseases of the pulmonary circulation, weight loss, deficiency anemia, drug abuse, and non-bleeding peptic ulcer)